INDUSTRY INSIGHTS

• How To Select The Right Viral Vector For Your Unique Therapy

  Choosing the wrong viral vector can compromise your therapy's safety and efficacy. Compare AAV, lentivirus, adenovirus, HSV, and emerging types across key manufacturing and clinical factors.

• Navigating An Uncertain Regulatory Environment For mRNA-Based Products

  mRNA developers face a regulatory gap: as of 2024, neither FDA nor EMA has issued CMC-specific guidelines. Learn how early regulator engagement and CDMO partnerships reduce risk.

• AAV Capsid Analysis With Single Particle Mass Photometry

  Accurate AAV capsid ratios are critical to gene therapy efficacy. See how mass photometry delivers faster, lower-cost E/F analysis with single-particle resolution.

• Revolutionizing Gene Therapy Manufacturing: Robotics, ML For Process Intensification

  By integrating perfusion into upstream manufacturing, see how this approach has achieved up to a fivefold increase in productivity, delivering titers that significantly exceed current industry benchmarks.

• Using Rapid Development Framework™ To Accelerate CGT Development, Manufacturing

  Learn how the following framework can accelerate your viral vector, CAR-T, and iPSC programs, reduce risk, and streamline your path from development to commercial manufacturing.

• From Promise To Patients: Smarter Pathways To Scale In Cell And Gene Therapy Manufacturing

  As the field evolves, the strategies developers choose may prove just as influential as the therapies themselves in determining how quickly innovation reaches patients.